Featured Research

from universities, journals, and other organizations

Dismissed Leukemia Drug Helps Chronic Lymphocytic Leukemia Patients, Studies Show

Date:
December 9, 2008
Source:
Ohio State University Medical Center
Summary:
A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia has shown promising results in two phase I and II clinical trials, according to new research.

A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia (CLL) has shown promising results in two phase I and II clinical trials, according to researchers at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.

Together, the trials involved 116 patients with advanced CLL who were treated with the drug flavopiridol (alvocidib). Responses were seen in approximately half of patients, many of whom had chromosomal abnormalities that made it unlikely they would be helped by standard therapies.

"Ohio State's success has reinvigorated interest in flavopiridol at the National Cancer Institute and other cancer centers," says Dr. Thomas Lin, a researcher and oncologist at Ohio State's Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.

Lin, the study's first author and a member of the Experimental Therapeutics program at Ohio State's Comprehensive Cancer Center, will discuss the findings during the 50th Annual Meeting of the American Society of Hematology (ASH). Lin will explain the research during the ASH-ASCO Joint Symposium on Sunday morning (12/7), and later that day during an oral presentation on CLL therapy.

Earlier this year at the annual meeting of the American Society of Clinical Oncology, Ohio State investigators made an oral presentation on a phase II study of 64 patients treated with flavopiridol. The novel drug is effective in resistant CLL that does not respond to other therapies. Each year, ASH selects five ASCO abstracts to be featured during the Joint Symposium.

Chronic lymphocytic leukemia is the most common type of adult leukemia, with some 15,000 new cases this year. While therapy has improved, CLL remains incurable and patients often suffer significant infections as a consequence of the disease and treatment.

In the 1980s, animal tests showed flavopiridol to be a potent cancer-fighter. But when researchers gave it to humans in repeated trials using a continuous prolonged infusion, the drug proved ineffective and was essentially forgotten.

What wasn't known then – and what Ohio State researchers discovered later – is that flavopiridol binds to proteins in human blood, which ties up much of the available drug and leaves less free drug in the bloodstream to kill cancer cells. In essence, patients were not getting enough of the drug to be effective.

Researchers at Ohio State devised a new dosing schedule for the drug to increase its anti-tumor activity.

The new schedule increased the drug's blood level enough to kill cancer cells in humans, says Dr. Michael Grever, chairman of the department of internal medicine and co-leader of the Experimental Therapeutics program at Ohio State's Comprehensive Cancer Center.

"Flavopiridol has bridged the way for several CLL patients to receive a curative stem cell transplant," says Dr. John Byrd, associate director of translational research and principal investigator of the phase II trial. Ohio State is now participating in a multi-center flavopiridol trial to see if other cancer centers have similar results with flavopiridol.

Ohio State researchers are also studying flavopiridol in patients with acute myloid leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma and head and neck cancers.

Other Ohio State cancer researchers involved in this study include Nyla A. Heerema, Dr. Gerard Lozanski, Beth Fischer, Dr. Kristie Blum, Dr. Leslie A. Andritsos, Dr. Jeffrey A. Jones, Dr. Joseph M. Flynn, Mollie E. Moran, Sarah Mitchell, Amy J. Johnson, Mitch Phelps.

Funding from the National Cancer Institute, Leukemia & Lymphoma Society and the CLL Research Consortium supported this research.


Story Source:

The above story is based on materials provided by Ohio State University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University Medical Center. "Dismissed Leukemia Drug Helps Chronic Lymphocytic Leukemia Patients, Studies Show." ScienceDaily. ScienceDaily, 9 December 2008. <www.sciencedaily.com/releases/2008/12/081208081012.htm>.
Ohio State University Medical Center. (2008, December 9). Dismissed Leukemia Drug Helps Chronic Lymphocytic Leukemia Patients, Studies Show. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2008/12/081208081012.htm
Ohio State University Medical Center. "Dismissed Leukemia Drug Helps Chronic Lymphocytic Leukemia Patients, Studies Show." ScienceDaily. www.sciencedaily.com/releases/2008/12/081208081012.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins